Lincoln Pharma gets a patent for Diclofenac Rectal Spray; stock climbs 6%

The company has necessary approvals from Drug Controller General of India (DCGI) and planning to launch it in the Indian market by January 2020.

Oct 22, 2019 07:10 IST India Infoline News Service

Ahmedabad based leading healthcare company, Lincoln Pharmaceuticals Limited has received a patent for its liquid Diclofenac Metered-Dose Rectal Spray (Diclofenac Rectal Spray). The patent has been awarded by the Government of India for "A Novel Liquid Rectal Spray Dosage Form Containing Diclofenac and Its Pharmaceutically Active Salts".

This Patent is valid for 20 years. The company has necessary approvals from Drug Controller General of India (DCGI) and planning to launch it in the Indian market by January 2020. The company is also planning to apply for a Global Patent for this novel solution.

Mahendra Patel, Managing Director, Lincoln Pharmaceuticals Limited, said, Globally, no liquid formulation of diclofenac for rectal administration is available. Lincoln Pharma will be the first company to introduce this novel solution aimed at better patient compliance, rapid drug release and greater bioavailability. We have developed this formulation with Diclofenac Sodium BP 25% WN, each squirt delivers Diclofenac Sodium 50 mg, Non-steroidal Anti-inflammatory Agent (NSAIDs). Due to this innovation, now patients can get far better results by using Diclofenac Rectal Spray as compared to the existing Diclofenac Suppository available in the market.

Diclofenac Rectal Suppository market is Rs20cr in India and growing at 16% per annum. The company see huge export potential for this product and will start product registration in markets including African continents, Latin America and Southeast Asian markets and gradually expand to other markets, the company said in the filing.

Lincoln Pharma's Liquid rectal spray dosage offers faster and better absorption of die drug resulting in quick relief and speedy recovery to patients compared to the existing therapeutic options. Clinical Trials conducted suggest that Diclofenac Rectal Spray is highly effective in patients suffering from pre and postoperative pain, gynaecological surgery and musculoskeletal disorders such as muscular pain, pain associated with arthritis, acute pain in renal colic and mild body ache, the company added. 

Shares of Lincoln Pharmaceuticals Ltd is currently trading at Rs161.50, up by Rs7.95 or 5.18% from its previous closing of Rs153.55 on the BSE.

Related Story